Introduction
============

LND is a general surgery strategy for oncology. However, unlike other urogenital cancers, such as penile, bladder, or prostate cancer, the effect of LND as a alternative treatment for patients with RCC is still controversial. The only piece of evidence regarding the treatment is the prospective, randomized-controlled trial EORTC 30881. Owing to the modification of the tumor, node, and metastases (TNM) classification system in 1978 and the low synthesize positive lymph node probability, the conclusions have been restricted [@B1]. Previously, a series of retrospective studies and meta-analyses have indicated that LND is unnecessary, even in high-risk RCC patients [@B2]-[@B4]. Several other retrospective studies have shown that LND improved the survival of RCC patients [@B5]-[@B7]. Nevertheless, in the 2018 EAU guidelines for renal cell carcinoma, LND was also recommended for high-risk renal cell carcinoma patients with evidence of level 2b disease [@B8]. Meanwhile, the American Joint Committee on Cancer (AJCC) updated the standards for the TNM system for RCC and placed invasion of the pelvicalyceal system under T3a. Given that there are so many confounding factors in this field, more accurate patient sampling and reducing relevant variables\' influences may bring new insights into this problem. Under this background, we conducted a retrospective cohort analysis of RCC patients at the pT3 stage to detect whether they benefited from LND.

Subjects/Patients and Methods
=============================

Clinical information
--------------------

In this study, 245 consecutive pT3 kidney cancer patients, who underwent open radical nephrectomy (RN) or laparoscopic RN with or without regional LND between January 2006 and December 2013 were included. pT3 was defined by the 2018 TNM system, which brought collective system invasion back into the standard. Lymph node invasion (LNI) was confirmed by two independent pathologists. All lymph node involvement/progressions were included.The exclusion criteria was failing to judge LN status (maybe ganglion), lack of clinical information and ectopic kidney tumor.

The clinical stage was based on the 2018 AJCC staging system. Among these patients, 63 (16.83%) were classified as having LNI, and 311 patients were negative for LNI. Table [1](#T1){ref-type="table"} shows the clinical and pathological characteristics of the cohort. The study was undertaken with approval from the People\'s Liberation Army General Hospital (PLAGH) institutional ethics committee board. All of the patients signed the approval statement.

Analytical methods
------------------

The clinicopathologic features were summarized with means/medians and compared by whether an LND was conducted, using the Student\'s t-test, Wilcoxon test, and the chi-square test. The propensity score for whether an LND was conducted was obtained using a logistic regression model with LND as the outcome and the features in Table [1](#T1){ref-type="table"} as covariates. A total of 134 patients formed the cohort for the propensity score (PS) analysis, which included 67 patients that underwent LND and 67 patients that did not. Then we calculated the effect size for the paired data and visualize the distribution of PS result.

The association of LND with the development of progression-free survival (PFS), cancer-specific survival (CSS), and overall survival (OS) was evaluated with Cox models using several PS techniques and summarized hazard ratio (HRs) and 95% confidence intervals (CIs). The PS techniques included 1:1 PS matching (n=67 pairs).

Then we selected pT3 RCC patients from TCGA database and extracted their overall survival time to conduct the K-M survival analysis as the external data set to test our conclusions.

At last, we divided patients into two groups based on the LN number. Then we further compared the survival time between the extended LND group (at least 5 LNs) and LND group (less than 5 LNs).

Statistical analyses were performed with the R software environment (version 3.4.0; <http://r-project.org/>), and *p* values \< 0.05 were considered statistically significant.

Results
=======

In total, 245 patients underwent RN for pT3 RCC, including 67 (27.3%) with LND, and 21 (8.57%) patients had LNI. The median number of LNs removed was 3 (1-18). The clinicopathologic features were compared using statistical methods, and we found that the tumor diameter and pathology results showed significant differences between the LND cohort and no LND cohort. Between the groups of with or without sarcoma, open surgery or laparoscopic surgery also showed a trend of differences. After balancing with the PS adjustment, none of the parameters showed a statistical difference. The median follow-up was 4.9 years. During this time, 80 (59.7%) patients had tumor progression, 64 patients died from RCC, and 70 patients survival. The balanced data, after PS matching, is shown in a distribution figure (Figure [1](#F1){ref-type="fig"}).All of the effective sizes were less than 0.2 that means the balance was successful.

Then, we conducted a Kaplan-Meier (K-M) survival analysis with the data for the matched pairs. The associations of LND with PFS, CSS, and OS were shown in Figure [2](#F2){ref-type="fig"}, Figure [3](#F3){ref-type="fig"}, and Figure [4](#F4){ref-type="fig"}, respectively. Then, we developed a Cox analysis to detect whether LND can be a risk factor for PFS, CSS, and OS. The results showed that LND was not significantly associated with PFS, CSS, or OS. The HRs for PFS, CSS, and OS were 1.19 (95% CI: 0.7624-1.856,*p* = 0.444), 1.064 (95% CI: 0.6439-1.758, *p* = 0.809), and 1.059 (95% CI: 0.6557-1.709, *p* = 0.816), respectively. As the M1 RCC patients were also included in the cohort, we then conducted another K-M survival analysis with the pT3M0 patients, and there was also no survival difference (Figure [S1](#SM0){ref-type="supplementary-material"}, S2, S3). We also analysed whether LND can benefit the RCC patients with inferior vena cava tumor thrombus which spread in the pT3a-pT3c and we got negative PFS and OS (Figure [S4](#SM0){ref-type="supplementary-material"}).

Within the TCGA database (2010-2014), we identified 182 pT3 renal cell carcinoma patients underwent RN with or without LND. Among them, 57 patients were M1, 121 were M0, and 4 were MX (deleted). Then we conducted K-M survival analysis in all patients and M0 patients for OS as their recurrence information is deficient. The results validated our previous conclusion that the survival time showed no difference between the LND group with the no LND group, HRs were 1.0376(95%Cl: 0.9638-1.587,*p*=0.865) and 1.019(95%Cl : 0.5659-1.836, *p*=0.949) in all patients and M0 patients, respectively (Figure [5](#F5){ref-type="fig"}, Figure [6](#F6){ref-type="fig"}).

Considering the LND number may also influence the oncologic outcome, we defined the removal of at least 5 LNs as extended LND and divided the patients into 2 groups: LND extended group (14 patients) and LND group (120 patients). The probability of LNI in LND extended group is 35.71%(5/14), but only 13.33%(16/120) in LND group. Interestingly, extended LND showed somehow negative effect on OS (HR=1.8805,95%Cl:0.9299-3.803, *p*=0.0387) in Figure [7](#F7){ref-type="fig"}, but CSS (HR=1.853,95% CI: 0.9122-3.764, *p* = 0.0832) and PFS(HR= 1.865,95% CI:0.9592-3.628, *p* = 0.0619) failed to achieve statistical difference, just showing some tendency (Figure [S6](#SM0){ref-type="supplementary-material"},S7).

Discussion
==========

The role of LND in RCC surgery can be traced to CJ Robson\'s research from 1969[@B9]. Regarding the issue of if LND can be beneficial for different subsets of RCC patients, the core problem became whether RCC patients will benefit or which subsets of patients will benefit. The only randomized evidence that the EORTC has provided failed to show a positive outcome, because they used the 1978 TNM system as a standard, which is quite different from today\'s standard, and the lymph node positive scale was so small that the conclusion was weakened.

During the past 2 decades, researchers have reduced the problem to whether any subset of RCC patients can benefit from LND. Given the fact that a benign lymph node dissection cannot improve survival and that the positive probability of T1 and T2 RCC is less than 4% [@B10], several predictive models have been introduced with different clinicopathologic features to predict the probability of lymph node invasion; for the high probability pN1 patients, LND may play a more important role. However, noe of the models have been widely used in clinical practice.

Much prospective research has focused on T2-T4 RCC patients or metastatic RCC patients, and the researchers have drawn controversial conclusions. Herrlinger et al [@B11] reported that for T3a RCC patients, an extended lymphadenectomy provided the greatest benefits compared to T1 or T2 patients. On the other hand, Capitanio et al found that from the prognostic perspective, a staging lymphadenectomy appeared to be most valuable in patients with T1-2 RCC [@B12]. Schafhauser et al suggested that for T1-T4 patients, at least 4% of all patients benefit from an extensive lymphadenectomy [@B13]. However, many recent researches have drawn the opposite conclusion that they did not identify a benefit from LND in either non-metastatic or cytoreductive settings [@B2],[@B14]. Gershman et al used propensity score techniques to balance the feather bias and reported that LND does not appear to provide a therapeutic benefit in patients with non-metastatic renal cell carcinoma [@B3]. Several researchers have focused on the question of whether mRCC patients can benefit from LND, and they usually reached a positive conclusion [@B6],[@B15].

Even different systematic reviews regarding LND have conflicted each other. Capitanio et al reported in 2013 that an extended LND may be beneficial, when technically feasible, in patients with local T3-T4 RCC [@B16], but Bhindi et al did not find any positive conclusions and suggested that LND was not associated with improved oncological outcomes [@B17]. Another review remained neutral. Bekema et al indicated that there was no robust evidence to suggest superior oncologic outcomes or worse perioperative outcomes for RCC patients with LND at the time of nephrectomy, compared with patients who had a nephrectomy alone for cT3-T4 RCC [@B18].

The number of LND or the LND template is controversial too. Capitanio et al divided their patients into 3 groups that the mean numbers of nodes removed were 3.1, 9.7 and 14.8 in patients undergoing limited, regional and extended LND, respectively. They found that the LND number may affect the CSS in pT2 RCC patients[@B19], Marchioni et al defined the LND number as the number of removed nodes(NRN) and patients were split into two groups: NRN≥3 and NRN \<3. Their finding showed that the NRN exerted a protective effect on CSS in pT2 but not in pT3 cohort[@B20]. Russo et al categorized their cohort into 3 groups based on the LND number (0-3,4-7,≥8) and they did not find any significant difference between LND number and PFS and OS[@B15]. Leibovich et al set the LND number cut-off point as 13, and they also got negative results in PFS and OS. Our findings that the LND number at least 5 show a negative effect on OS was opposite to the previous study. This is probably because the extended LND group always has a larger tumor diameter (10 vs 6.875, p = 0.0004). In the RCC surgery practice, the LND number varies a lot from country to country and surgeon to surgeon. This makes it difficult to standardize different study. As the various LND template exists, the LND number as a standard requires more discussion.

In our study, we have collected the largest single-center RCC patient dataset in China. With the background that the AJCC updated the TNM system standards, the invasion of the pelvicalyceal system joined the system again as a poor prognostic factor. Considering the fact that the controversy over LND has mostly focused on T3 and T4 RCC, and T3 stage is consisted of three heterogeneous factors, we attempted to examine a pT3 only retrospective cohort and utilized the PS score to calibrate our results.

Several limitations restricted our research. First, the standards of LND have not been defined. An extended LND and standard LND were regarded as a whole LND in our research. Furthermore, the standard regarding whether to perform an LND is also ambiguous. It mostly depends on the particular surgeon\'s experience. However, we matched open nephrectomy and laparoscopic nephrectomy as a propensity parameter to reduce the bias from different approaches. Several reports [@B5],[@B19] have pointed out that an extended LND may be more often recommended for pT3 RCC, at least to improve the PFS. These findings need future study. Second, the simple scale was limited, as LND is not prevalent in Chinese clinical practice, from the lack of definitive benefit but improving the anesthesia time and difficulty. Third, this research was limited by its retrospective and non-randomized design. To perform the propensity score analysis, 111 patients were excluded, which weakened the influence of the data. As the low probability of lymph node invasion and the nephron-sparing surgery become more and more popular, there is little chance for a prospective, randomized-controlled trial to be conducted worldwide, but multiple centers and larger samples cohort retrospective trials are also needed in the future. LND or extended LND may still be a method to be recommended for some subsets of RCC patients, but we do not know the classification methods.

Conclusion
==========

Radical nephrectomy with LND cannot improve PFS, CSS, or OS for pT3 RCC patients.
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###### 

The clinical and pathological characteristics of the cohort.

                                overall cohort(n=245)                matched cohort(n=134)                                        
  ----------------------------- ----------------------- ------------ ----------------------- --------- --------- -------- ------- -------
  **gender**                                                         0.34129                                              0.853   0.123
  male                          133                     46                                             45        46               
  female                        45                      21                                             22        21               
  **mean(median)age**           53.95(55.00)            53.51        0.821                             54.7      53.51    0.629   0.054
                                                                                             (56.0)    (56.00)                    
                                                        (56.00)                                                                   
  **mean(median)BMI (n=194)**   25.11(24.87)            24.61        0.2821                            24.36     24.56    0.787   0.074
                                (25.04)                                                      (24.18)   (25.01)                    
  **ECOG PS**                                                        0.495                                                0.771   0.097
  1                             154                     50                                             60        60               
  \>1                           24                      7                                              7         7                
  **mean(median)diameter**      6.342(6.000)            7.51(8.00)   0.0404\*                          6.893     7.51     0.377   0.115
                                                                                                       (7.000)   (8.00)           
  **symptoms**                                                       0.0917                                               0.856   0.076
  no                            136                     44                                             43        44               
  yes                           42                      23                                             24        23               
  **necrosis**                                                       0.365                                                0.471   0.036
  no                            130                     45                                             41        45               
  yes                           48                      22                                             26        22               
  **sarcoma**                                                        0.191                                                0.573   0.123
  no                            166                     59                                             61        59               
  yes                           12                      8                                              6         8                
  **WHO/ISUP(n=201/n=96)**                                           0.2188                                               0.476   0.135
  1-2                           88                      17                                             23        17               
  3-4                           63                      28                                             28        28               
  **thrombosis**                                                     0.209                                                0.299   0.035
  no                            119                     39                                             33        39               
  yes                           59                      28                                             34        28               
  **collecting system**                                              0.545                                                0.723   0
  no                            74                      25                                             27        25               
  yes                           104                     42                                             40        42               
  **fat invasion**                                                   0.166                                                0.723   0.099
  no                            123                     40                                             42        40               
  yes                           55                      27                                             25        27               
  **metastasis**                                                     0.102                                                0.484   0
  no                            156                     57                                             30        26               
  yes                           22                      10                                             37        41               
  **pathology**                                                      0.0198\*                                             0.249   0.104
  ccRCC                         159                     51                                             55        51               
  pRCC                          8                       7                                              7         7                
  chRCC                         3                       1                                              0         1                
  collecting duct RCC           4                       6                                              4         6                
  other types                   4                       2                                              1         2                
  **operation**                                                      0.152                                                0.598   0.186
  open RN                       126                     41                                             38        41               
  laparoscopic RN               52                      26                                             29        26               
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